Pre-Seed Round
Target: $500k
Funding will accelerate core product development and support our initial clinical pilots with key healthcare partners.
Share a few details and we'll send you our latest investor deck.
Invest in Healus.today
Healus is a human-centered mental health technology company bridging the gap in care. We empower providers and patients with tools for continuous support between traditional appointments, ensuring no one walks their journey alone.
Seed Round
Target: Get in touch
Focused on scaling our hardware manufacturing, expanding the clinical team, and growing our nationwide distribution network.
Tell us about your fund or background and we'll follow up.
Investor Roadmap
A detailed snapshot of our funding target, strategic validation, and scaling milestones.
Current Round
Pre-Seed
Target Funding
$500,000
Use of Funds
Product & Pilots
Timeline
Q3 2026 - Q2 2027
Milestone 1 — Foundation & Concept
Completed
What we proved
-
Mapped the clinical failure point - the unmonitored window between appointments where relapse and crisis events were most likely to occur - validated across 40+ structured conversations with patients, therapists, and prescribers.
-
Confirmed no existing solution addressed continuous, real-time support outside of scheduled care, establishing the gap as structural, not incidental.
-
Built the founding clinical rationale for hardware-enabled intervention, grounded in behavioral health literature on adherence, treatment dropout, and crisis response patterns.
-
Launched Healus.today - brand live, investor page active, and waitlist open. First market signal confirmed.
Milestone 2 — Technology & Eco-system
Now
What we are doing right now
-
Building the core technology stack - product architecture is scoped, development sprints are running, and prototype milestones are being tracked against pilot readiness.
-
Meeting directly with psychiatrists, therapists, and clinical leads to pressure-test product design against real care workflows - decisions are being made from clinical reality, not assumptions.
-
Maintaining 3 active investor conversations with early-stage funds that have health-tech and hardware exposure; data room and pitch deck are prepared and current.
-
Applying to YC-tier accelerator and fellowship cohorts (Q2/Q3 2026 cycles) to access capital, mentorship, and institutional validation in parallel with direct fundraising.
-
Pursuing non-dilutive capital through health innovation grants and NIH SBIR pathways to extend runway independent of the primary raise timeline.
Milestone 3 — Pre-Seed Close & First Pilots
Q3 2026
What will be true by Q3 2026
-
Pre-seed round will close at $500K - every dollar pre-allocated to product completion, clinical pilot operations, and legal/regulatory groundwork. No discretionary spend.
-
A functional, testable prototype will be deployed with 1–2 clinical partners under a structured observation protocol with defined intake, usage, and outcome tracking.
-
Baseline engagement and safety metrics will be live - the first real-world data that builds the seed round story from evidence, not projections.
-
FDA device classification strategy will be confirmed with health-law counsel and documented for investor and regulatory audiences.
-
Primary revenue model will be selected - SaaS per-seat, payer reimbursement, or health system licensing - based on direct pilot learnings rather than assumption.
Milestone 4 — Seed Round & Scaled Operations
Post-Seed
Where the pre-seed data takes us
-
Seed round ($2M–$5M) will be raised on the back of clinical outcomes data, early revenue, and a proven pilot model, not projections or narrative alone.
-
Manufacturing will scale with contracted supply chain partners; quality and safety protocols will be in place before any broad distribution begins.
-
A clinical success team will own partner onboarding, outcomes monitoring, and provider retention - ensuring scale doesn't come at the cost of efficacy.
-
Payer and health system partnership conversations will open with real-world outcomes data as leverage, initiating the reimbursement pathway that makes adoption sustainable.
-
Unit economics will be proven at pilot scale before nationwide rollout - expansion will be deliberate, market by market, not a land grab.
Milestone 5 — Category Standard
Vision
The inevitable destination
-
Heal will be embedded as standard-of-care infrastructure across outpatient mental health, integrated care, and crisis intervention workflows, the layer that exists between every appointment.
-
Reimbursable through major payer networks with CPT code strategy executed in partnership with health system allies, making clinical adoption frictionless and economically viable.
-
Peer-reviewed outcomes data will be published, cementing credibility with regulators, academic medical centers, and institutional capital.
-
Global expansion into markets where mental health infrastructure gaps are acute and regulatory pathways are accessible - starting with highest-burden, lowest-coverage regions.
-
Category-defining exit: strategic acquisition by a major health system or med-tech platform, or IPO as the established leader in continuous, hardware-enabled mental health care.